Citations

Clear

11 citation(s) found for "Lee, Dae Ho".

The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists
Lee, Hyunsuk , Christie, Hannah E. , Lee, Ji Seon , Kwon, Woo Il, Moon, Min Kyong , Choi, Sung Hee , Lee, Dae Ho , Lee, Seunggeun , Kho, Minjung , Man, Chiara Dalla , Cho, Nam H. , Park, Jongseok , Jo, Yeeun , Boscolo, Federica , Dalla Man, Chiara , Cho, Nam H , Choi, Jaewon , Vella, Adrian , Kwak, Soo Heon , Kim, Jong-Il , Park, Kyong Soo , Christie, Hannah E , Lee, Hyunbeom , Boscolo, Francesca S. , Lee, Jeongeun, Lee, Sangwon , Vella, Adrian

Mayo Clinic

Diabetes Care | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2337/dc26-0662 | PMID 42561183 Get It

OBJECTIVE Genetic variation in the glucagon-like peptide 1 receptor (GLP1R) has been implicated in type 2 diabetes (T2D) risk and treatment response. We investigated whether GLP1R R131Q, which was previously reported as a T2D-protective variant in genome-wide association studies, alters receptor signaling, β-cell function, and response to glucagon-like peptide 1 receptor agonists (GLP-1RAs). RESEARCH DESIGN AND METHODS Trajectory of β-cell function was evaluated in a 20-year community-based prospective cohort in Korea (n = 6,373), where participants underwent biennial 2-h 75-g oral glucose tolerance tests, and disposition index was used as surrogate marker. Pharmacogenetic response to GLP-1RAs was assessed in a hospital-based T2D cohort in Korea (n = 177). Hyperglycemic clamp studies (n = 17), human islet experiments (n = 21), and in vitro assays were conducted to characterize GLP1R R131Q effects on receptor signaling and islet function. RESULTS GLP1R R131Q was associated with slower decline in disposition index in individuals without T2D, with reductions from baseline of 30% in homozygous carriers, 35% in heterozygotes, and 37% in wild-type individuals. In people with T2D, each allele conferred an additional 0.53% or 5.8 mmol/mol reduction in HbA1c after 6 months of GLP-1RA treatment (P = 5.8 × 10−4). Hyperglycemic clamp and human islet experiments demonstrated allele-dependent enhancement of GLP-1RA–stimulated insulin secretion (P = 0.050 and P = 0.037, respectively). In vitro, GLP1R R131Q increased GLP-1RA–stimulated cAMP production with directional observations consistent with pathway bias. CONCLUSIONS GLP1R R131Q is a gain-of-function variant associated with preservation of β-cell function and enhanced glycemic response to GLP-1RA treatment, supporting further investigation as a candidate pharmacogenetic marker for precision diabetes care.
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
Besse, Benjamin, Subbiah, Vivek, Curigliano, G., Bowles, Daniel W. , Doebele, Robert C. , Mansfield, Aaron S. , Baik, Christina S. , Lopes, Gilberto , Paz-Ares, Luis , Taylor, Matthew H. , Tan, Daniel S.W., Alonso, G. , Gadgeel, Shirish M., Kalemkerian, Gregory P. , Ou, S.-H.I., Wekken, Anthonie J. van der , Becerra, Carlos R., Evangelist, Makenzi Colleen, Griesinger, Frank, Lou, Yanyan , Mazières, Julien, Melear, Jason M., Narang, Mohit , Saxena, Ashish, Thomas, Michael, Thomassen, Amber , Lee, Dae Ho, Kim, Dong-Wan, Gainor, Justin F., Subbiah, Vivek , Besse, Benjamin , Besse, Benjamin , Subbiah, Vivek , Curigliano, Giuseppe , Tan, Daniel S W , Gadgeel, Shirish , Ou, Sai-Hong I , van der Wekken, Anthonie J , Liu, Stephen V , Lou, Yanyan , Mazières, Julien , Melear, Jason M , Narang, Mohit , Thomas, Michael , Lee, Dae Ho , Kim, Dong-Wan , Gainor, Justin F , Mansfield, Aaron S , Bowles, Daniel W , Curigliano, Giuseppe , Paz‐Ares, Luis , Gadgeel, Shirish M. , Griesinger, Frank , Liu, Stephen V. , Saxena, Ashish , Thomas, Michael , Wang, Sophia Y. , Kim, Dong‐Wan , Gainor, Justin F. , Taylor, Matthew H.

Mayo Clinic

Journal of Clinical Oncology | March 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1190-1197

10.1200/jco-25-01489 | PMID 41886723 Get It

RET fusions appear in 1%-2% of non–small cell lung cancers (NSCLCs). The results from the ARROW study (ClinicalTrials.gov identifier: NCT03037385 ) supported US Food and Drug Administration approval of pralsetinib, an oral selective RET inhibitor, for metastatic RET -altered NSCLC and RET fusion–positive thyroid cancers. ARROW was a phase I/II open-label study of pralsetinib 400 mg once daily in RET fusion–positive NSCLCs. Coprimary end points were overall response rate (ORR) and safety. Key secondary end points included duration of response, progression-free survival, and overall survival (OS). At data lock (May 20, 2024), 281 patients initiated pralsetinib (median treatment duration, 15.0 months). ORR (measurable disease patients; n = 259) was 78% (95% CI, 69 to 86) for treatment-naïve patients and 63% (95% CI, 54 to 71) for prior platinum-based chemotherapy patients. Median OS was 44.3 months (95% CI, 30.9 to 53.1), 50.1 months (95% CI, 28.3 to not reached) in treatment-naïve patients, and 39.7 months (95% CI, 27.8 to 53.2) in prior platinum patients. Common grade ≥3 treatment-related adverse events were anemia (21%), hypertension (15%), and decreased neutrophils (13%). Three treatment-related deaths occurred (pneumonia, n = 2; interstitial lung disease and rhabdomyolysis, n = 1 each). Safety was consistent with previous ARROW reports; no hypersensitivity was reported in patients receiving prior immunotherapies. Pralsetinib produced robust, durable responses with manageable safety in treatment-naïve and previously treated patients with RET fusion–positive NSCLCs, confirming previous findings with longer follow-up.
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Waliany, Sarah , Cooper, Alissa J. , Liu, Stephen V. , Gautschi, O., Rotow, Julia K. , Smith, Katherine E. , Weber, Urs, Lee, Dae Ho , Loong, H., Patel, Jyoti D. , Nagasaka, Misako , Patel, Shetal , Tan, Daniel S. W., Solomon, Benjamin J., Pall, Georg , Riess, Jonathan W. , Sun, Lova , Früh, Martin, Uy, Natalie F., Gadgeel, Shirish, Feng, Jamie, Leighl, Natasha B., Baik, Christina S. , Lai, G., Ou, S. Ignatius, Cheung, Kingsley S.Y., Patil, Tejas, Weiler, Daniela , Yeap, Beow Y., Wirth, Lori J. , Gainor, Justin F., Drilon, Alexander D., Lin, Jessica J., Loong, Herbert H. , Rotow, Julia , Gautschi, Oliver , Smith, Katherine E R , Weber, Urs M , Loong, Herbert H , Pennell, Nathan A , Nagasaka, Misako , Patel, Shetal A , Tan, Daniel S W , Solomon, Benjamin J , Kim, Tae Min , Pall, Georg , Riess, Jonathan W , Sun, Lova , Früh, Martin , Uy, Natalie F , Gadgeel, Shirish , Feng, Jamie , Do, Andrew , Falcon, Christina , Leighl, Natasha B , Baik, Christina S , Lai, Gillianne G Y , Ou, Sai-Hong I , Cheung, Kingsley S Y , Patil, Tejas , Mansfield, Aaron S , Weiler, Daniela , Yeap, Beow Y , Wirth, Lori J , Gainor, Justin F , Drilon, Alexander , Lin, Jessica J , Liu, Stephen V , Früh, Martin , Gadgeel, Shirish M. , Feng, Jamie , Mansfield, Aaron S. , Gainor, Justin F.

Mayo Clinic

Clinical Cancer Research | January 15, 2026 | Volume: 32 | Issue: 6 | Pages: 1157-1168

10.1158/1078-0432.ccr-25-4382 | PMID 41537704 Get It

Abstract Purpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” a global consortium of patients with advanced RET-altered solid tumors who received SRI and underwent postprogression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with the Kaplan–Meier method. Results: RETgistry included 109 patients with RET-altered advanced solid tumors (lung, n = 94; thyroid, n = 15) who underwent 143 post-SRI progression biopsies (tissue, 91; plasma, 52). The median PFS and TTD were 13.9 months [95% confidence interval (CI), 10.1–16.6] and 17.3 months (95% CI, 14–20.2), respectively. Secondary RET mutations were detected in 20 (14%) biopsies [lung cancer, 15 (12.4%) and thyroid carcinoma, 5 (22.7%)]. Common acquired off-target alterations involved MET (18.2%; amplification, 15%), TP53 (8.2%), APC (7.6%), KRAS (7.1%), KEAP1 (5.9%), and CDKN2A/B (5.3%). MET alterations were enriched in post-SRI versus pre-SRI specimens (full cohort, 17.6% vs. 2.0%, P = 0.022; lung cancer, 19.1% vs. 2.1%, P = 0.022). Conclusions: The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.
Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.
Zanwar, Saurabh , Goel, Utkarsh , Chao, Austin, Lien, Kyle, Mazzoni, Sandra , Khouri, Jack , Cassano, Raffaella Cassano , Addison, Daniel , Dominick, Anthony, Green, Kimberly M , Sborov, Douglas W. , Shetty, Sanath Kumar , Vazquez‐Martinez, Mariola , Avila, Gabriel De, Dixon, Ariel, Blue, Brandon , Freeman, Ciara L. , Ali, Hossam M. , Alomar, Mohammed , Alsina, Melissa , Shain, Kenneth H. , Davis, James A. , Davis, James A , Ali, Hossam M , Lee, Dae Hyun , Dima, Danai , Chao, Austin, Banerjee, Rahul , Williams, Louis S. , Anwer, Faiz , Lin, Yi , Cheng, Richard , Davis, James, Julian, Kelley , Shetty, Sanath, Locke, Frederick L. , Baz, Rachid , Puglianini, Omar Castañeda , Hansen, Doris K. , Grajales‐Cruz, Ariel , Raza, Shahzad

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4066-4066

10.1182/blood-2025-4066 Get It

Abstract Introduction: Teclistamab is the first FDA approved BCMA-directed bispecific antibody for the treatment of relapsed and refractory multiple myeloma (RRMM). With BCMA-targeting CAR-T therapies, cytokine release syndrome (CRS) is a risk factor for cardiotoxicity. Teclistamab was associated with fatal cardiovascular adverse events (CVAEs) in a recent US pharmacovigilance database analysis, but this analysis was limited by reporting bias. Therefore, the aim of our study is to conduct a multicenter study to define the real-world incidence of CVAEs in RRMM patients treated with teclistamab. Method We performed a retrospective multi-center cohort study of patients receiving teclistamab at 5 medical centers. Baseline oncologic and cardiovascular characteristics (including vital sign and echocardiographic data) were collected. Baseline cardiovascular disease (CVD) was defined as presence of coronary artery disease, congestive heart failure, severe or symptomatic valvular heart disease, or stroke at baseline. CVAE was collected and categorized based on CTCAE v5.0 by each institution. Major adverse cardiovascular event (MACE) was a composite outcome with any of the following: congestive heart failure, asymptomatic cardiomyopathy (interval LVEF drop >10% to resultant LVEF less than 50%), coronary artery disease requiring intervention, stroke or cardiovascular death. Arrhythmia was a composite outcome with any of the following: atrial tachyarrhythmia, ventricular tachyarrhythmia or bradyarrhythmia. Median follow-up was calculated through reverse Kaplan-Meier method. Multivariable Cox regression analysis was used to define the relation between MACE and survival. Cause of death was categorized as myeloma-related death or non-myeloma-related deaths (i.e. CRS, infection or cardiovascular death). Cause-specific Cox regression was performed to define relationship between MACE and cause of death. Results In a cohort of 219 patients treated with teclistamab with median follow-up of 20.1 months, 7.3% (N=16) developed MACE, 7.3% (N=16) developed arrhythmia and 12.8% (N=28) developing any MACE or arrhythmia. MACE occurred at a median of 4.5 days (IQR 2.25-15.75 days) after teclistamab step-up. The incidence of MACE was 16.4% in patients with baseline CVD versus 2.7% in those without baseline CVD (p<0.001). Patients who developed MACE had inferior ECOG performance status (PS) (PS >=2: 62.5% vs. 27.7%; p=0.008). Additionally, baseline hemoglobin level (9 vs 10g/dL; p=0.072) was numerically lower in MACE, compared to no MACE. There was no difference in age, sex, bone marrow (BM) plasma cell burden, ferritin, C-reactive protein or LDH levels between MACE vs. no MACE group. Patients who developed MACE had lower baseline diastolic blood pressure (67.7 vs 73.8mmHg; p=0.041) and numerically lower LVEF (51.4 vs 59.3%; p=0.059; baseline echocardiogram performed in 86% of all cohort). Patients who developed MACE had similar incidences of CRS (Grade >=2: 25.0 vs 16.7%; p=0.620) and immune effector cell-associated neurotoxicity (ICANS) grade 2 or higher (12.5 vs 7.5%; p=0.812). In multivariable Cox regression analysis, MACE was independently associated with inferior overall survival (HR 2.72; 95% CI 1.41-5.25; p=0.003), after adjusting for baseline CVD, age, high BM burden, extramedullary disease, and plasma cell leukemia. In cause-specific multivariable Cox regression analysis, MACE was independently associated with non-myeloma-related death (HR: 10.77 95% CI 4.39- 26.41; p<0.001) but not with myeloma-related death (1.54; 95% CI 0.64- 3.70; p=0.336). Conclusion In conclusion, in this large, real-world multicenter study, we observed that MACE occurred in over 7% of patients following teclistamab for RRMM, typically within 2 weeks of initiation. MACE was significantly associated with increased non-myeloma-related mortality. In contrast to CAR-T therapy, CRS or ICANS were not associated with MACE, whereas majority of patients who developed MACE had ECOG PS >=2 or baseline cardiovascular disease. More studies are necessary to define mechanisms and strategies to reduce these MACE and improve survival. Patients with baseline cardiovascular disease or poor performance status may benefit from cardiovascular optimization before and during teclistamab therapy.
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects
Herrmann, Joerg , Carver, Joseph R. , Cheng, Richard K. , Daniele, Andrés J., Deych, Elena , Lee, Dae Hyun , Lyon, Alexander R, Fradley, Michael G. , Macedo, Ariane Vieira Scarlatelli , Mooradian, Meghan J. , Nohria, Anju, Porter, Charles , Rassaf, Tienush, Sverdlov, Aaron L. , Thavendiranathan, Paaladinesh, Neilan, Tomas G. , Mitchell, Joshua D. , Mitchell, Joshua D , Sverdlov, Aaron L , Cheng, Richard , Lee, Dae H , Barac, Ana , Dent, Susan , Lenihan, Daniel , Leong, Darryl P. , Liu, Jennifer , López‐Fernández, Teresa , Lyon, Alexander R. , Nohria, Anju , Rassaf, Tienush , Suero‐Abreu, Giselle Alexandra

Mayo Clinic

JAMA Oncology | November 13, 2025 | Volume: 12 | Issue: 1 | Pages: 90

10.1001/jamaoncol.2025.4543 | PMID 41231466 Get It

Importance The introduction of immune checkpoint inhibitor (ICI) therapy has improved cancer outcomes but at the cost of adverse events, mainly related to the immune system. Cardiovascular (CV) toxic effects, and especially myocarditis, are of particular concern and are the subject of this position statement by the International Cardio-Oncology Society with representation of experts from oncology, hematology, and cardiology. Observations CV toxic effects of ICI therapies include inflammation-associated diseases, such as myocarditis, pericarditis, and vasculitis, as well as the aggravation of chronic inflammatory conditions, such as atherosclerosis with acute ischemic complications (myocardial infarction and stroke). Patients taking ICI therapies can also develop cardiac dysfunction, stress-induced cardiomyopathy (Takotsubo or apical ballooning syndrome), and heart failure without inflammatory cell infiltration of the myocardium. Atrial and ventricular arrhythmias can emerge in the setting of a systemic inflammatory milieu, myocarditis, or ischemia. Of all potential CV adverse effects, myocarditis remains of highest concern, although fatality rates have declined over time with a broadening spectrum of presentations ranging from troponin elevation of uncertain significance to smoldering, nonsevere, and severe or fulminant myocarditis. Conclusions and Relevance Concerns for myocarditis continue to dominate the spectrum of CV toxic effects in patients receiving ICI therapy. Recommendations for management vary according to severity. Multidisciplinary collaborations remain key for managing acute toxic effects and future cancer treatment decisions, including ICI rechallenge. Ischemic heart disease constitutes the main differential diagnosis in these patients, while pericarditis can be concomitantly present, and atrial and ventricular arrhythmias can also complicate the clinical picture. Several gaps in knowledge are identified and require further research.
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin Axis
Vincelette, Nicole D. , Yu, Xiaoqing , Moon, Jungwon , Su, Siyuan , Cheng, Chia‐Ho, Sammut, Rinzine , Razabdouski, Tiffany N. , Nguyen, Hai V. , Eksioglu, Erika A. , Ali, Najla Al , Patel, Parth , Lee, Dae Hyun , Nakanishi, Shima , Hyjek, Elizabeth , Murphy, Daniel J. , Lee, Daesung , Kuykendall, Andrew , Moon, Jungwon , Su, Siyuan , Cheng, Chia-Ho , Sammut, Rinzine , Razabdouski, Tiffany N , Nguyen, Hai V , Eksioglu, Erika A , Chan, Onyee , Al Ali, Najla , Patel, Parth C , Lee, Dae H , Nakanishi, Shima , Ferreira, Renan B , Hyjek, Elizabeth , Mo, Qianxing , Cory, Suzanne , Lawrence, Harshani R , Zhang, Ling , Murphy, Daniel J , Komrokji, Rami S , Lee, Daesung , Kaufmann, Scott H , Cleveland, John L , Yun, Seongseok , Chan, Onyee , Zhang, Ling , Komrokji, Rami S. , Kaufmann, Scott H. , Cleveland, John L. , Yun, Seongseok

Mayo Clinic

Blood Cancer Discovery | May 7, 2024 | Volume: 5 | Issue: 4 | Pages: 276-297

10.1158/2643-3230.bcd-23-0210 | PMID 38713018 Get It

Abstract Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPN) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies, particularly for patients with triple-negative (TN) myelofibrosis (MF) who lack mutations in the JAK2 kinase pathway and have very poor clinical outcomes. Here we report that MYC copy number gain and increased MYC expression frequently occur in TN-MF and that MYC-directed activation of S100A9, an alarmin protein that plays pivotal roles in inflammation and innate immunity, is necessary and sufficient to drive development and progression of MF. Notably, the MYC-S100A9 circuit provokes a complex network of inflammatory signaling that involves numerous hematopoietic cell types in the bone marrow microenvironment. Accordingly, genetic ablation of S100A9 or treatment with small molecules targeting the MYC-S100A9 pathway effectively ameliorates MF phenotypes, highlighting the MYC–alarmin axis as a novel therapeutic vulnerability for this subgroup of MPNs. Significance: This study establishes that MYC expression is increased in TN-MPNs via trisomy 8, that a MYC-S100A9 circuit manifest in these cases is sufficient to provoke myelofibrosis and inflammation in diverse hematopoietic cell types in the BM niche, and that the MYC-S100A9 circuit is targetable in TN-MPNs.
MYC-Alarmin Axis As a Novel Oncogenic Driver in a Subgroup of Triple Negative Myeloproliferative Neoplasms
Yu, Xiaoqing , Moon, Jungwon , Su, Siyuan , Cheng, Chia‐Ho, Sammut, Rinzine , Ali, Najla H. Al, Patel, Parth , Nakanishi, Shima , Lee, Daesung , Su, Siyuan , Patel, Parth C , Vincelette, Nicole D. , Kuykendall, Andrew , Nguyen, Hai V. , Eksioglu, Erika A. , Chan, Onyee , Lee, Dae Hyun , Ferreira, Renan B , Mo, Qianxing , Cory, Suzanne , Lawrence, Harshani R , Zhang, Ling , Murphy, Daniel J. , Komrokji, Rami S. , Kaufmann, Scott H. , Cleveland, John L. , Yun, Seongseok

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 994-994

10.1182/blood-2023-174383 Get It

Primary Myelofibrosis (PMF) is an aggressive myeloproliferative neoplasm (MPN) characterized by constitutional symptoms, cytopenias, splenomegaly, extramedullary hematopoiesis, bone marrow (BM) fibrosis, and a propensity to transform to acute myeloid leukemia (AML). Despite advances in understanding the underlying genetic abnormalities in MPN and the development of JAK2 inhibitors to treat MF, there is an urgent need to devise new treatment strategies, particularly for triple negative myelofibrosis (TN-MF) cases that lack mutations in the JAK2 kinase pathway and who have inferior outcomes. To identify potential oncogenic drivers in TN-MF, we performed cytogenetic analyses and targeted exome sequencing of 98 genes commonly mutated in myeloid malignancies in 584 MF patients identified from the Total Cancer Care database at Moffitt Cancer Center. Notably, there were no significant differences in the somatic mutation profiles (other than JAK2 activating mutations) between TN vs. JAK2/CALR/MPL mutant MF patients. However, trisomy of chromosome 8 occurs more frequently in TN-MF vs. other subtypes (26.7% vs. 6.2%, p=0.0001). To identify oncogenic drivers in trisomy 8+ TN-MF, we performed scRNA-seq analysis from 18,651 cells ( n=15,850 from 3 normal donors and n=2,801 from a trisomy 8+ TN-MF patient) and identified a total of 1,260 genes that are differentially regulated in hematopoietic stem cells (HSCs) of trisomy 8+ TN-MF compared to normal donors. Among these, 131 genes were located on chromosome 8 and MYC was one of the top 5 genes that are significantly upregulated in trisomy 8+ HSCs. Additional immunohistochemistry staining demonstrated that MYC protein levels in BM cells were significantly higher in trisomy 8+ TN-MF patients vs. trisomy 8- patients. To assess whether MYC might be a driver of MPN, we established an Mx1-Cre +/-;Rosa26 LSL-MYC/LSL-MYC transgenic mouse model that inducibly overexpresses MYC in HSCs following treatment of polyinosinic-polycytidylic acid (pIpC). Forced MYC expression induced profound anemia, monocytosis, megakaryocytic atypia, splenomegaly, increased BM collagen deposition/fibrosis, extramedullary hematopoiesis in spleen and liver, and significantly reduced OS vs. Mx1-Cre +/- wild type controls (median OS 258 days vs. not reached (NR), p<0.0001). MYC also promoted expansion of HSCs, myeloid progenitors, and Gr-1 +/CD11b + mature myeloid cells in BM and spleen; thus, MYC was sufficient to provoke MF-like disease independent of JAK2 pathway mutations. Subsequent scRNA-seq analysis of 25,232 cells ( n=13,552 from control and n=11,680 from a MYC transgenic mouse) revealed that S100a9 mRNA levels were increased by MYC in most major hematopoietic cell types. Supporting oncogenic roles of S100A9 in MYC-driven MF, deletion of S100a9 in Mx1-Cre +/-;Rosa26 LSL-MYC/LSL-MYC;S100a9 -/- mice abolished MYC-induced MF phenotypes and significantly improved OS (median OS NR vs. 225 days, p=0.0345). To test whether inhibition of MYC can suppress MF disease progression in vivo, lethally irradiated CD45.1 +/CD45.2 + WT mice were transplanted with BM cells harvested from CD45.2 + Mx1-Cre +/-;Rosa26 LSL-MYC/LSL-MYC mice that were treated with pIpC 20 weeks prior to transplant. MYCi975, a small molecule that inhibits MYC, reduced MYC and S100a9 protein levels in BM and spleen cells. Further, MYCi975 effectively suppressed MYC-driven MF phenotypes and disease progression, and significantly improved OS (median OS NR vs. 252 days, p=0.0109). In summary, our studies are the first to describe an oncogenic role of MYC in MF pathogenesis, where MYC provokes an alarmin-driven inflammatory circuit, and where the MYC-S100A9 axis represents a therapeutic vulnerability for TN-MF patients. Accordingly, our results provide a strong rationale for testing agents targeting MYC or S100A9 in early phase clinical trials in MPNs having increased MYC levels or activity.
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
Smith, Katherine E. , Lee, Dae Ho, Nagasaka, Misako , Patel, Jyoti D. , Früh, Martin , Pall, Georg , Uy, Natalie F., Riess, Jonathan W. , Wirth, Lori J. , Yeap, Beow Y., Gainor, Justin F. , Lin, Jessica Jiyeong, Smith, Katherine E R , Cooper, Alissa J. , Drilon, Alexander , Rotow, Julia , Liu, Stephen V. , Gautschi, Oliver , Lee, Dae Ho , Loong, Herbert H. , Pennell, Nathan A , Solomon, Benjamin , Lin, Jessica Jiyeong

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 9065-9065

10.1200/jco.2023.41.16_suppl.9065 Get It

9065 Background: Rearranged during transfection ( RET) gene alterations are the oncogenic driver in diverse tumor types, including RET fusions identified in 1-2% of non-small cell lung cancers (NSCLC). While RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib are effective, acquired drug resistance remains a challenge. Here, we report the initial results from the RETgistry, an international consortium aimed at elucidating mechanisms of resistance to RET TKIs across RET-altered solid tumors. Methods: This was a retrospective analysis performed across 16 institutions. Patients (pts) were eligible if they had advanced solid tumor harboring an oncogenic RET alteration, received ≥1 RET TKI with disease progression, and underwent resistant tumor or liquid biopsy for next-generation sequencing (NGS). Results: A total of 103 time-distinct biopsies (62 tissue, 30 plasma, 11 paired tissue/plasma) were included in analysis, obtained from 88 pts with progression on a RET-selective TKI [selpercatinib (n = 70), pralsetinib (n = 14), selpercatinib and pralsetinib sequentially (n = 4)]. Pts had the following tumor types: 72 NSCLC (69% KIF5B-RET, 21% CCDC6-RET, 10% other RET fusion), 13 medullary thyroid cancer (TC) (54% RET M918T, 46% other RET mutation), and 2 papillary and 1 anaplastic TC (all, RET fusion). Median age was 58 (range, 21-86); 48% were male with 89% never/light smokers. Median duration of RET TKI preceding biopsies [first-line, n = 32 (31%); second-line, n = 42 (41%); third-/greater-line, n = 29 (28%)] was 16.5 months (mos) (95% CI, 14.0-19.6); median PFS was 14.1 mos (95% CI, 9.3-17.0). Resistant biopsies were obtained at median 15.0 mos from TKI initiation (range, 1.8-58.8). Acquired RET mutations were detected in 14 (14%), most common being G810 substitutions in 12 (12%). Potential off-target resistance gene alterations identified in 43 cases (42%) included MET amplification (14%), BRAF V600E or fusion (2%), KRAS gain or mutation (5%), ERBB2 amplification (2%), EGFR amplification (3%), ROS1 fusion (1%), and activating PIK3CA mutation or PTEN loss (4%). No resistant lung cancer biopsy demonstrated small cell transformation. The duration of TKI therapy (HR 0.64, p = 0.11) or PFS (HR 0.75, p = 0.33) did not differ according to the presence of on-target vs off-target resistance. NGS analyses of pre-RET-selective TKI tumors (n = 92) revealed frequent co-occurring alterations in TP53 (29%) and CDKN2A/B (12%). Conclusions: On-target resistance to RET inhibition due to acquired RET mutations was less common than off-target resistance, identified in 14%. The majority of RET TKI resistance is mediated by off-target mechanisms such as bypass receptor tyrosine kinase activation. Further studies are warranted to enable the development of therapeutic strategies to address resistance in pts with RET-altered tumors. The RETgistry accrual and data analyses continue.
Delayed Cutaneous Fluid Leakage after Fluoroscopic-Guided Epidural Steroid Injection
D’Souza, Ryan S. , Woods, Charonn D., Lee, Dae-Woong , Bendel, Markus A. , Lee, Daewoong, Bendel, Markus, D'Souza, Ryan S , Lee, Daewoong, Kissoon, Narayan

Mayo Clinic

Pain Medicine | March 16, 2021 | Volume: 22 | Issue: 12 | Pages: 3092-3095

10.1093/pm/pnab108 | PMID 33755154 Get It